Texas SB 241: Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.

Status: Effective on . . . . . . . . . . . . . . . (as of 2023-05-27)

State: Texas · Session: 88 · Bill: SB 241

Subjects: DIABETES (S0486), HEALTH & HUMAN SERVICES COMMISSION (V0177), Health--Other Diseases & Medical Conditions (I0383), Insurance--Health & Accident (I0422), MEDICINE & PRESCRIPTION DRUGS (S7338)

Sponsors: Perry, Talarico

View Texas SB 241 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.